Review



obstructive sleep apnea  (Apnimed Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Apnimed Inc obstructive sleep apnea
    Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent <t>obstructive</t> sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).
    Obstructive Sleep Apnea, supplied by Apnimed Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/obstructive+sleep+apnea/med_rxiv__64898__2026__03__10__26348040-211-6-0?v=Apnimed+Inc
    Average 86 stars, based on 1 article reviews
    obstructive sleep apnea - by Bioz Stars, 2026-07
    86/100 stars

    Images

    1) Product Images from "Effects of CPAP on OSA-related cardiovascular risk markers: a two-week CPAP withdrawal and re-initiation study"

    Article Title: Effects of CPAP on OSA-related cardiovascular risk markers: a two-week CPAP withdrawal and re-initiation study

    Journal: medRxiv

    doi: 10.64898/2026.03.10.26348040

    Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent obstructive sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).
    Figure Legend Snippet: Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent obstructive sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).

    Techniques Used:

    Patients followed at the Centre d’Investigation et de Recherche sur le Sommeil, for CPAP therapy were assessed for eligibility and included between 12 January 2024 and 12 May 2025. Included participants then underwent an ambulatory CPAP discontinuation screening period to confirm persistent obstructive sleep apnoea (OSA) off treatment. Participants with an apnoea-hypopnoea index (AHI) <15 events/h on ApneaLink™ after 4 nights without CPAP were excluded. Participants who met the screening criterion were subsequently enrolled into the interventional phase. The final analysis included those who completed all three visits with adherence to the CPAP withdrawal and re-initiation protocol.
    Figure Legend Snippet: Patients followed at the Centre d’Investigation et de Recherche sur le Sommeil, for CPAP therapy were assessed for eligibility and included between 12 January 2024 and 12 May 2025. Included participants then underwent an ambulatory CPAP discontinuation screening period to confirm persistent obstructive sleep apnoea (OSA) off treatment. Participants with an apnoea-hypopnoea index (AHI) <15 events/h on ApneaLink™ after 4 nights without CPAP were excluded. Participants who met the screening criterion were subsequently enrolled into the interventional phase. The final analysis included those who completed all three visits with adherence to the CPAP withdrawal and re-initiation protocol.

    Techniques Used:



    Similar Products

    obstructive sleep apnea  (Apnimed Inc)
    86
    Apnimed Inc obstructive sleep apnea
    Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent <t>obstructive</t> sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).
    Obstructive Sleep Apnea, supplied by Apnimed Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/obstructive+sleep+apnea/med_rxiv__64898__2026__03__10__26348040-211-6-0?v=Apnimed+Inc
    Average 86 stars, based on 1 article reviews
    obstructive sleep apnea - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    unau obstructive sleep apnea  (Wolters Kluwer Health)
    86
    Wolters Kluwer Health unau obstructive sleep apnea
    Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent <t>obstructive</t> sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).
    Unau Obstructive Sleep Apnea, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/obstructive+sleep+apnea/10__1097_slash_hjh__0000000000004219-17-7-3?v=Wolters+Kluwer+Health
    Average 86 stars, based on 1 article reviews
    unau obstructive sleep apnea - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    obstructive sleep apnea devices  (Osaka Organic Chemical Industry Ltd)
    86
    Osaka Organic Chemical Industry Ltd obstructive sleep apnea devices
    Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent <t>obstructive</t> sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).
    Obstructive Sleep Apnea Devices, supplied by Osaka Organic Chemical Industry Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/obstructive+sleep+apnea/pm40975996-184-15-21?v=Osaka+Organic+Chemical+Industry+Ltd
    Average 86 stars, based on 1 article reviews
    obstructive sleep apnea devices - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    obstructive sleep apnea lemborexant sleep hypnotics dual orexin receptor antagonist  (Eisai Inc)
    86
    Eisai Inc obstructive sleep apnea lemborexant sleep hypnotics dual orexin receptor antagonist
    Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent <t>obstructive</t> sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).
    Obstructive Sleep Apnea Lemborexant Sleep Hypnotics Dual Orexin Receptor Antagonist, supplied by Eisai Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/obstructive+sleep+apnea/pm40848323-12-110-93?v=Eisai+Inc
    Average 86 stars, based on 1 article reviews
    obstructive sleep apnea lemborexant sleep hypnotics dual orexin receptor antagonist - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    obstructive sleep apnea  (Kjellberg Inc)
    90
    Kjellberg Inc obstructive sleep apnea
    Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent <t>obstructive</t> sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).
    Obstructive Sleep Apnea, supplied by Kjellberg Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/obstructive+sleep+apnea/pm40524276-297-7-6?v=Kjellberg+Inc
    Average 90 stars, based on 1 article reviews
    obstructive sleep apnea - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent obstructive sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).

    Journal: medRxiv

    Article Title: Effects of CPAP on OSA-related cardiovascular risk markers: a two-week CPAP withdrawal and re-initiation study

    doi: 10.64898/2026.03.10.26348040

    Figure Lengend Snippet: Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent obstructive sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).

    Article Snippet: Apnimed is developing pharmacological treatments for Obstructive Sleep Apnea.

    Techniques:

    Patients followed at the Centre d’Investigation et de Recherche sur le Sommeil, for CPAP therapy were assessed for eligibility and included between 12 January 2024 and 12 May 2025. Included participants then underwent an ambulatory CPAP discontinuation screening period to confirm persistent obstructive sleep apnoea (OSA) off treatment. Participants with an apnoea-hypopnoea index (AHI) <15 events/h on ApneaLink™ after 4 nights without CPAP were excluded. Participants who met the screening criterion were subsequently enrolled into the interventional phase. The final analysis included those who completed all three visits with adherence to the CPAP withdrawal and re-initiation protocol.

    Journal: medRxiv

    Article Title: Effects of CPAP on OSA-related cardiovascular risk markers: a two-week CPAP withdrawal and re-initiation study

    doi: 10.64898/2026.03.10.26348040

    Figure Lengend Snippet: Patients followed at the Centre d’Investigation et de Recherche sur le Sommeil, for CPAP therapy were assessed for eligibility and included between 12 January 2024 and 12 May 2025. Included participants then underwent an ambulatory CPAP discontinuation screening period to confirm persistent obstructive sleep apnoea (OSA) off treatment. Participants with an apnoea-hypopnoea index (AHI) <15 events/h on ApneaLink™ after 4 nights without CPAP were excluded. Participants who met the screening criterion were subsequently enrolled into the interventional phase. The final analysis included those who completed all three visits with adherence to the CPAP withdrawal and re-initiation protocol.

    Article Snippet: Apnimed is developing pharmacological treatments for Obstructive Sleep Apnea.

    Techniques: